To validate YAP/TEAD signaling as a potential therapeutic target for OS treatment, we evaluated the effect of verteporfin and CA3, two Hippo/YAP inhibitors, on primary tumor growth in a preclinical model of OS. The gene discussed is YAP1; the disease is neoplasm.